Garbuzov reported an increase in the volume of drug production in Moscow

The Binnopharm Moscow production site, part of the Binnopharm Group, increased the volume of drug production by 34% compared to last year in the first nine months of 2025. This was announced by Anatoly Garbuzov, Head of the Moscow Investment and Industrial Policy Department.

From January to September 2025, the company increased the volume of production of medicines to 5.3 million packages, Garbuzov said. At the same time, a quarter of the volume was directed to export, he noted. "The company has the status of an industrial complex, which gives it a number of tax benefits and allows it to invest additional funds in the development of production," the head of the department emphasized.

Shipments of the plant's products to the CIS countries increased 3.6 times during the reporting period, reaching 1.4 million packages. The key sales markets driving this growth are Azerbaijan, Georgia, Kyrgyzstan, Tajikistan, and Uzbekistan. Drugs for the treatment of diseases of the respiratory system have made a significant contribution to the export dynamics. Among them, aerosol stands out, the volume of supplies of which abroad is estimated at millions of pieces, the department said.

The Binnopharm plant, which has the status of an industrial complex, is a biotechnological site of the company. The main products include medicines for the treatment of respiratory diseases, immunomodulatory agents and vaccines. In the near future, the company plans to produce drugs based on monoclonal antibodies, which will take the company to a new technological level and strengthen its position as one of the key full-cycle manufacturers in Russia.

All important news is on the Izvestia channel in the MAX messenger.